The NeurologyLive® headache and migraine clinical focus page offers information, podcasts, videos, and news and interviews with physicians related to the care of patients with headache disorders such as chronic and episodic migraine, cluster headache, tension-type headache, and more. The page includes updates on the latest FDA actions, clinical guidelines, and study and clinical trial findings.
August 29th 2025
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 29, 2025.
Galcanezumab Improves Episodic Migraine In Patients With Prior Failures
December 13th 2019Treatment with the calcitonin gene-related peptide (CGRP) inhibitor resulted in significant improvements in monthly migraine headache days across the groups assessed, including a significantly greater number of patients with ≥50% and ≥75% reductions.
Experts Weigh In On Early Clinical Experience With Nerivio Migra in Acute Migraine
November 28th 2019With Theranica’s Nerivio Migra acute migraine device named a top invention of the year, three experts in migraine shared their insight into its clinical application in the early days of its availability, with varying experiences.
Topiramate Liquid Formulation IND Gets Regulatory Go-Ahead
November 21st 2019The investigational new drug application for OWP Pharmaceuticals’ first-ever liquid formulation of topiramate, intended to offer a new delivery alternative for the therapy in epilepsy and migraine treatment, has been approved.
Ubrogepant Provides Significant Relief From Migraine Pain, Bothersome Symptoms
November 19th 2019An analysis of ACHIEVE II suggests that the oral CGRP antagonist from Allergan provides significant pain freedom and relief of the most bothersome symptoms for adults with migraine for at least one dose assessed.
Migraine Treatment With Galcanezumab Not Associated With Cardiovascular Events
November 15th 2019Pooled analysis from 3 studies of more than 1000 patients with migraine suggest that galcanezumab (Emgality, Eli Lilly) has good cardiovascular safety and is not linked with vasoconstriction or an increase in cardiovascular adverse events.
DHE Infusion Coupled With Adjunctive Care Successful in Refractory Pediatric Migraine
November 10th 2019The comprehensive aggressive migraine protocol (CAMP), combining DHE infusion and multidisciplinary care, significantly reduced headache intensity and frequency among other measures in a small group of patients.
Fremanezumab Shows Rapid Efficacy in Chronic Migraine
November 6th 2019A new analysis from the phase 3 HALO development program showed that Teva’s CGRP inhibitor fremanezumab (Ajovy) separated from placebo by Day 2 posttreatment, suggesting not only rapid clinical improvement, but the potential to positively impact treatment adherence.
Disease-Specific, Mechanism-Based Migraine Treatments: Only The Beginning
November 1st 2019In Part 2 of this interview, Amaal Starling, MD, assistant professor of neurology at Mayo Clinic Scottsdale, discussed what still needs to be done in the migraine space in light of recent advancements and how disease-specific therapies are just the beginning for the field.
Migraine Care Reaps the Benefits of Novel Treatments, With More on the Way
October 31st 2019In Part 1 of this interview, Amaal Starling, MD, assistant professor of neurology at Mayo Clinic Scottsdale, shared her experiences with a number of new migraine drugs and devices and the impact that more options will have on clinical practice.